19 March 2020

Tumor necrosis factor (TNF) inhibitors are increasingly applied during pregnancy without clear knowledge of the impact on placenta and fetus. In a recent paper published in Clinical Pharmacology and Therapeutics, researchers from the Departments of Pharmacology and Toxicology, Obstetrics and Gynecology, and Health Evidence, in collaboration with Sanquin Diagnostic Services, investigated the placental handling of the TNF inhibitors infliximab and etanercept.
 
In their study, Gaby Eliesen and colleagues combined clinical observations with preclinical studies. In clinical work, the placental drug disposition was studied in women with autoimmune diseases who were treated with TNF inhibitors throughout pregnancy. In the preclinical studies, fetal and maternal circulations of term human, TNF-inhibitor-naïve, placentas were re-established immediately after birth. In a controlled laboratory setting, it was then studied how the placenta handled the drugs in the initial six hours after first exposure ex vivo.
 
A main finding of the study was that infliximab concentrations in placenta tissue reached markedly higher levels than etanercept. This was observed both in the clinical cases as well as in the ex vivo perfused placentas. The authors indicate that the difference in placental tissue exposure may be of clinical relevance and warrants further investigation. More specifically, future studies should look into the occurrence of placental TNF inhibition and possible consequences thereof.
 
 
 

Related news items


Midsummer Night Event 2022

28 June 2022

Last week, over 250 PhD candidates and postdocs from DCMN, RIHS and RIMLS joined the inspiring and tasty Midsummer Night Event. Check out the pictures to see the impression!

read more

The future of laboratory animal research More attention to living conditions of laboratory animals

16 May 2022

On May 9, a meeting took place at the Radboudumc as a result of the launch of the Dutch Transparency Agreement on Animal Testing. The Radboudumc is one of the twenty signatories and has thus committed itself to openly and transparently communicate its vision and policy with regard to animal testing.

read more

Plugging the gap ZonMw/Health Holland grant

3 March 2020

RIMLS en RIHS researchers Willeke Daamen, Frank Vandenbussche, Joris van Drongelen, Toin van Kuppevelt and Janneke Grutters have been granted 1.3 million euro for the development and evaluation of a new technology to prevent premature rupture of fetal membranes (iPPROM).

read more

TURBO grants for four medical-technical research projects

8 November 2018

Four TURBO grants were awarded to new technical-medical research proposals. The grants are part of the TURBO program, a collaboration between Radboudumc and the University of Twente.

read more

Ten new members for Academia Europaea

15 September 2017

Ten Radboud professors have been appointed to the Academia Europaea, the European association of scientists who are among the best in the world.

read more

Four Veni grants for young Radboudumc researchers

28 July 2017

Four researchers from Radboudumc have been awarded a Veni grant the Netherlands Organisation for Scientific Research (NWO). These grants provide highly promising young scientists with the opportunity to further elaborate their own ideas during a period of three years.

read more